Skip to content
LATEST
Business

Pfizer licenses Starna CAR-T programs for $330m upfront

Starna can receive up to $2.3 billion in milestones and royalties if the pre-IND autoimmune programs advance and win approvals.

Pfizer licenses Starna CAR-T programs for $330m upfront

Pfizer said in a Wednesday press release it licensed three Starna Therapeutics in vivo CAR-T programs for autoimmune diseases, agreeing to pay $330 million upfront for rights outside Greater China.

The deal gives Pfizer control of early autoimmune cell-therapy assets and leaves Starna eligible for up to $2.3 billion in development and commercial milestones, plus royalties on approved-product sales.

In vivo CAR-T refers to chimeric antigen receptor T-cell therapy designed to alter T cells within the body. Pfizer said the three programs are pre-IND, meaning they are before the regulatory filing that typically precedes U.S. human testing.

“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases,” Michael Vincent, Pfizer’s chief inflammation and immunology officer, said in the press release. He said the patients who might benefit most are “those for whom today’s options fall short.”

Pfizer said it will lead clinical development outside Greater China and plans to make finished drug product for initial clinical trials at its facilities in the United States. The company also said it will hold sole commercial control outside Greater China for all products covered by the license.

“Our vision at Starna is to unlock the potential of RNA medicines to transform patient care,” Rongkuan Hu, Starna’s chief executive officer, said in the release. He said Starna’s targeted LNP delivery platform and RNA technology could support in vivo CAR-T therapies.

The agreement also gives Pfizer rights to use Starna’s in vivo CAR-T technology in inflammation and immunology, and in oncology. Pfizer also receives options to license compounds from a separate research collaboration and to expand its territory to include Greater China.

For Pfizer, the license adds to its inflammation and immunology pipeline and extends its work in RNA delivery into a next-generation cell-therapy approach. For Starna, the structure provides a large upfront payment while preserving potential future economics tied to development, commercial progress and net sales.

The release did not include human safety or efficacy data for the programs, did not identify specific autoimmune diseases targeted by the three assets and did not give a trial-start date. Pfizer’s disclosure notice said forward-looking information about the pipeline, Starna’s technology and the agreement involves substantial risks and uncertainties.

The next visible steps are regulatory and clinical-development milestones for the pre-IND programs, including any future filing or trial announcement by Pfizer.

Source: Pfizer press release, Nov. 18, 2026

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news